-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 12, Hansen Pharmaceuticals and OliX Pharmaceuticals jointly announced that the two parties have signed a licensing and cooperation agreement to discover, develop and commercialize siRNA therapies for key targeted indications in China
The two companies will use the GalNAc-asiRNA platform of OliX Pharmaceuticals and the strong R&D, production and commercialization capabilities of Hansen Pharmaceuticals Group in China to develop multiple hepatocyte-targeted products, including cardiovascular and metabolic And other indications
According to the cooperation agreement, OliX Pharmaceuticals will use the GalNAc-asiRNA technology platform to discover lead drugs and ensure the development of drug candidates for specific targets, including cardiovascular, metabolic diseases and other liver-related diseases
Down payment of US$6.
OliX Pharmaceuticals is a clinical-stage pharmaceutical company.